November 2 2019 | Targeted Therapies in Oncology

Synergism of Immune Checkpoint Inhibitors and Antibody-Drug Conjugates Induce Promising Response Rates

November 22, 2019

Clinical Articles

Building upon the initial successes of anti–PD-1 and anti–CTLA-4 therapies has been a major focus of drug development over the past several years—basically, in search of other agents that could generate “immune-synergy.” What the term means and implies is critically important: It refers to drugs that work better together than alone (or in sequence) through their individual mechanisms of action to enhance the host immune-response to cancer.

FGFR2 Emerges as a Promising Target in Cholangiocarcinoma

November 20, 2019

Clinical Articles

Given the frequency of FGFR2 alterations in intrahepatic cholangiocarcinoma, investigators have identified it as a potential prognostic indicator of survival and a rational target of systemic cancer therapies.

Next-Generation Sequencing Can Improve Treatment Decisions, But Community Uptake Remains Delayed

November 18, 2019

Clinical Articles

Precision medicine has afforded oncologists the opportunity to develop individualized approaches to treat non–small cell lung cancer, one of the most devastating malignant disorders, which until the past decade was thought to be invariably fatal within months.